Last reviewed · How we verify
Rimegepant 25 MG (rimegepant-25-mg)
Rimegepant 25 MG, developed by Pfizer Inc., is a small molecule used for the acute treatment of migraine with or without aura in adults and prevention of migraine in adults. It is a first-in-class calcitonin gene-related peptide receptor antagonist. Rimegepant has shown clinical differentiation in its efficacy and safety profile compared to other migraine treatments. Its commercial significance lies in its ability to provide rapid and sustained relief from migraine symptoms. The drug has been marketed and has a moderate revenue stream. There are no notable pipeline developments for rimegepant.
At a glance
| Generic name | rimegepant-25-mg |
|---|---|
| Sponsor | Pfizer |
| Drug class | calcitonin gene-related peptide receptor antagonist |
| Target | calcitonin gene-related peptide receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Acute treatment of migraine with or without aura in adults
- Prevention of migraine in adults
Common side effects
- Nasopharyngitis
Drug interactions
- Warfarin
- P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole, itraconazole, erythromycin, quinidine, ritonavir, saquinavir)
- P-glycoprotein inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort)
- Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, ritonavir, saquinavir)
- Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort)
- CYP3A substrates (e.g., midazolam, triazolam, lovastatin, simvastatin, atorvastatin, fentanyl)
Key clinical trials
- Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) (PHASE3)
- Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimegepant 25 MG CI brief — competitive landscape report
- Rimegepant 25 MG updates RSS · CI watch RSS
- Pfizer portfolio CI